MedTrace Logo

TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke

NCT02963545 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2016-11-17

No results posted yet for this study

Summary

Single-center, prospective, descriptive and biomedical research with controls, without health product.

Depression is the second risk factor for stroke as tobacco smoking following hypertension. Peripheral abnormalities in serotonin parameters were described in depression and tobacco smoking. The investigators hypothesized dysregulations in pathways of serotonin (5-HT), which has notably complex vasomotor effects and of kynurenine which could have cognitive dysfunction effects.

The aim of this study is to evaluate simultaneously the involvement of serotonin and kynurenine pathways parameters in patients suffering from a cerebral infarction shortly after the onset (less than 4 hours and a half), within a 2 days follow-up (Day 1 and Day 2) and 3 months after the cerebral infarction.

Conditions

  • Cerebral Infarction

Interventions

OTHER

Usual care patients in neurology department

patients characteristics, history, clinical signs chronology and usual medical care by the emergency units, cerebral infarction area

BIOLOGICAL

blood and urines sampling

Collection samples for biochemical determinations of serotonin pathway and kynurenine pathway parameters determinations

PROCEDURE

Psychiatric evaluation

depression scale, impulsivity scale, hostility scale , tobacco consumption questioning

Sponsors & Collaborators

  • Versailles Hospital

    lead OTHER

Principal Investigators

  • Odile SPREUX-VAROQUAUX, PhD · Pharmacology, Versailles Hospital and Versailles University

  • Fernando PICO, Neurology Department head · Versailles Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-11-30
Completion
2016-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02963545 on ClinicalTrials.gov